89bio, Inc. (ETNB) Covered Calls
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.
There are no covered calls available for 89bio, Inc..
Born To Sell's covered call screener gives you full search capabilities so you can find stocks and ETFs that make good covered call candidates.
Want to make money with covered calls? Sign Up For A Free Trial
| Top 10 Open Interest For Nov 21 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | IBIT covered calls | 6. | INTC covered calls | 1. | GHRS covered calls | |
| 2. | KVUE covered calls | 7. | TLT covered calls | 2. | IREN covered calls | |
| 3. | NVDA covered calls | 8. | ASST covered calls | 3. | SRPT covered calls | |
| 4. | SLV covered calls | 9. | EEM covered calls | 4. | UPST covered calls | |
| 5. | GLD covered calls | 10. | HYG covered calls | 5. | HUT covered calls | |
Want more examples? ETN Covered Calls | ETQ Covered Calls
